INNOVIVA, INC. Deferred Federal Income Tax Expense (Benefit)
INNOVIVA, INC. (INVA) reported Deferred Federal Income Tax Expense (Benefit) of $42.74 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-25
- INNOVIVA, INC. deferred federal income tax expense (benefit) for fiscal 2025 was $42.74M.
- INNOVIVA, INC. deferred federal income tax expense (benefit) for fiscal 2024 was -$12.61M, a 291.17% decline from fiscal 2023.
- INNOVIVA, INC. deferred federal income tax expense (benefit) for fiscal 2023 was $6.59M, a 74.66% decline from fiscal 2022.
- INNOVIVA, INC. deferred federal income tax expense (benefit) for fiscal 2022 was $26.03M, a 63.29% decline from fiscal 2021.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $42.74M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$12.61M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $6.59M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $26.03M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $70.89M 10-K/A · filed 2024-03-05 | -$70.89M 10-K · filed 2022-02-28 |
| 2020-12-31 | $60.41M 10-K · filed 2023-02-28 | |
| 2019-12-31 | -$41.57M 10-K/A · filed 2022-03-17 | $41.57M 10-K · filed 2020-02-19 |
| 2018-12-31 | -$190.19M 10-K · filed 2021-02-25 | $190.19M 10-K · filed 2019-02-19 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-19 | |
| 2016-12-31 | $0.00 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |